Credit: Shutterstock photoGlobal major in musculoskeletal healthcare, Zimmer Biomet Holdings, Inc.ZBH recently launched a X-ray-based Patient Specific Instrument, X-PSI Knee System. This is the world's first CE Marked surgical planning system which enables patient specific implant positioning, solely utilizing X-ray technology.
X-PSI Knee System enables surgeons to use X-ray images to generate three-dimensional anatomic models. Then the patient's anatomy will be analyzed by using Zimmer Biomet's Patient Specific Instruments Planner so that the 3D customized surgical plan can be developed. That plan will lead to improved joint implant fit and placement accuracy. This new version of Zimmer Biomet Patient Specific Instruments now offers standard of care preoperative X-ray imaging instead of Magnetic Resonance Imaging (MRI) and Computerized Tomography (CT) scans.
Initially, X-PSI Knee System will be introduced in five countries across the European Union.
Over the past six months, Zimmer Biomet has been trading above the Zacks categorized Medical - Products industry. The company has gained 24.5%, when compared to the 20.9% gain of the broader industry.
According to a BCC Research report, the global market for joint reconstruction and replacement is expected to increase to nearly $16.2 billion by 2018, at a CAGR of 4.2% from 2013 through 2018. The U.S. market is expected to reach a worth of $10.3 billion by 2018 at a CAGR of 5.1%. The European and Japanese markets are estimated to reach $4.5 billion and $1.3 billion by 2018, at CAGRs of 3.3% and 1.4%, respectively. Thus, the company has bountiful opportunities both domestically and internationally.
Recent Developments
The company is now focused on transitioning the new Persona partial knee into full commercial launch during the second half of the year. This latest addition to the Persona product line will complete the partial knee portfolio.
Zacks Rank and Key Picks
Zimmer Biomet currently carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Align Technology, Inc. ALGN , Inogen, Inc. INGN and Accelerate Diagnostics, Inc. AXDX . Notably, Inogen sports a Zacks Rank #1 (Strong Buy), while Align Technology and Accelerate Diagnostics carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock has added roughly 33.6% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has gained around 22.5% over the last three months.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30%. The stock has added roughly 15.8% over the last three months.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Inogen, Inc (INGN): Free Stock Analysis Report
Accelerate Diagnostics, Inc. (AXDX): Free Stock Analysis Report
Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
